SunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE